ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0880

Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks

Georg Schett1, Filip Van den Bosch2, Xenofon Baraliakos3, David Sandoval4, Vladimir Geneus4, Rebecca Bolce4, Soyi Liu-Leage5, Andris Kronbergs4 and Philip Mease6, 1Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 2Ghent University Hospital, Ghent, Belgium, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 4Eli Lilly and Company, Indianapolis, 5Eli Lilly and Company, Indianapolis, IN, 6Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

Meeting: ACR Convergence 2020

Keywords: Biologicals, clinical trial, Disease-Modifying Antirheumatic Drugs (Dmards), Interleukins, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of disease: radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA). The distinction between the two is defined by the presence or absence of radiographic changes at the SI joints. Both subtypes may have extra-articular manifestations such as peripheral enthesitis, increasing the disease burden and decreasing quality of life (QoL). Ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A. It has shown efficacy in clinical trials for r- and nr-axSpA as well as psoriasis and PsA. This post-hoc analysis explores the efficacy of ixekizumab in improving enthesitis, overall disease activity and QoL in patients with r-axSpA, who are biologic DMARD-naïve (COAST-V) or previously exposed to TNF inhibitors (COAST-W), or patients with nr-axSpA (COAST-X).

Methods: Patients with enthesitis at baseline from three Phase 3, randomized, double-blind, placebo (PBO)-controlled studies [COAST-V (NCT02696785), COAST-W (NCT02696798), and COAST-X (NCT02757352)] examining the efficacy and safety of ixekizumab in patients with r-axSpA or nr-axSpA. Ixekizumab (80 mg) or PBO were given SC every 2 (Q2W) or 4 (Q4W) weeks during a double-blind 16-week treatment period, with a starting dose of 80 mg or 160 mg at Week 0. Here, we explore the efficacy of ixekizumab at week 16 in resolving peripheral enthesitis in patients as assessed by Spondyloarthritis Research Consortium of Canada (SPARCC). We also compare the % patients achieving Assessment of Spondyloarthritis International Society 40 (ASAS40), Ankylosing Spondylitis Disease Activity Score (ASDAS) < 2.1 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50), change from baseline (CFB) in BASFI and 36-Item Short Form Health Survey (SF36-PCS) in patients achieving and not achieving SPARCC=0. Missing data were imputed using non-responder imputation for categorical data and modified baseline observation carried forward for continuous data.

Results: 543 Patients had enthesitis at baseline. In patients with r-axSpA, 48.6% and 67.6% achieved resolution of peripheral enthesitis (SPARCC=0) at week 16 in the IXE80Q4W and IXE80Q2W groups, respectively, compared to only 22.9% in the PBO group. For the patients with nr-axSpA, resolution of peripheral enthesitis at week 16 was observed in 52.2% and 57.7% in the IXE80Q4W and IXE80Q2W groups, respectively, while enthesitis resolved in 31.3% of PBO patients. The % of patients achieving ASDAS < 2.1 and BASDAI50 were also greater for the IXE80Q4W and IXE80Q2W groups vs PBO for both r-axSpA and nr-axSpA (Table 2). Patients with enthesitis resolution with ixekizumab showed improvements in BASFI and SF36-PCS compared to PBO for both r-axSpA and nr-axSpA (Table 3). Improvements were also seen in patients with SPARCC >0 at week 16.

Conclusion: Ixekizumab is effective in resolving enthesitis and improvements in overall disease activity and QoL in patients with r-axSpA and nr-axSpA.

Table 1. ASAS40, ASDAS-LDA and BASDAI50 responses in all patients, patients with remission of peripheral enthesitis (SPARCC=0) or patients with no remission of peripheral enthesitis (SPARCC>0) at Week 16

Table 2. BASFI and SF-36 responses in all patients, patients with remission of peripheral enthesitis (SPARCC=0) or patients with no remission of peripheral enthesitis (SPARCC>0) at Week 16


Disclosure: G. Schett, None; F. Van den Bosch, AbbVie, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Gilead, 5, Merck, 5, 8; X. Baraliakos, AbbVie, 2, 5, 8, Novartis, 2, 5, 8, Celgene, 5, 8, Chugai, 5, 8, Pfizer, 5, 8, UCB, 5, 8, BMS, 5, 8, Merck, 5, 8, Galapagos, 5; D. Sandoval, Eli Lilly and Company, 3; V. Geneus, Eli Lilly and Company, 3, 4; R. Bolce, Eli Lilly and Company, 1, 3; S. Liu-Leage, Eli Lilly and Company, 3, 4; A. Kronbergs, Eli Lilly and Company, 1, 3; P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5.

To cite this abstract in AMA style:

Schett G, Van den Bosch F, Baraliakos X, Sandoval D, Geneus V, Bolce R, Liu-Leage S, Kronbergs A, Mease P. Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/ixekizumab-improves-signs-and-symptoms-of-patients-with-radiographic-and-non-radiographic-axial-spondyloarthritis-and-extra-articular-manifestation-of-enthesitis-through-16-weeks/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ixekizumab-improves-signs-and-symptoms-of-patients-with-radiographic-and-non-radiographic-axial-spondyloarthritis-and-extra-articular-manifestation-of-enthesitis-through-16-weeks/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology